This following article is written for Prof. Abba Kastin's Festschrift, to add to the tribute to his important role in the advancement of the role of peptides in physiological, as well as pathophysiological processes. There have been many advances during the 35 years of his prominent role in the Peptide field, not only as editor of the journal Peptides, but also as a scientific investigator and editor of two volumes of the Handbook of Biological Active Peptides [146,147]. Similar to the advances with many different peptides, during this 35 year period, there have been much progress made in the understanding of the pharmacology, cell biology and the role of (bombesin) Bn receptors and their ligands in various disease states, since the original isolation of bombesin from skin of the European frog Bombina bombina in 1970 [76]. This paper will briefly review some of these advances over the time period of Prof. Kastin 35 years in the peptide field concentrating on the advances since 2007 when many of the results from earlier studies were summarized [128,129]. It is appropriate to do this because there have been 280 articles published in Peptides during this time on bombesin-related peptides and it accounts for almost 5% of all publications. Furthermore, 22 Bn publications we have been involved in have been published in either Peptides [14,39,55,58,81,92,93,119,152,216,225,226,231,280,302,309,355,361,362] or in Prof. Kastin's Handbook of Biological Active Peptides [137,138,331].

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4641779PMC
http://dx.doi.org/10.1016/j.peptides.2015.04.026DOI Listing

Publication Analysis

Top Keywords

bombesin receptors
8
receptors ligands
8
peptides
8
peptide field
8
handbook biological
8
biological active
8
active peptides
8
published peptides
8
advances
5
insights bombesin
4

Similar Publications

Radiopharmaceutical therapy (RPT) is an emerging prostate cancer treatment that delivers radiation to specific molecules within the tumor microenvironment (TME), causing DNA damage and cell death. Given TME heterogeneity, it's crucial to explore RPT dosimetry and biological impacts at the cellular level. We integrated spatial transcriptomics (ST) with computational modeling to investigate the effects of RPT targeting prostate-specific membrane antigen (PSMA), fibroblast activation protein (FAP), and gastrin-releasing peptide receptor (GRPR) each labelled with beta-emitting lutetium-177 (Lu) and alpha-emitting actinium-225 (Ac).

View Article and Find Full Text PDF

Prostate cancer (PC) represents the second most diagnosed form of cancer in men on a global scale. Despite the theranostic efficacy of prostate-specific membrane antigen (PSMA) radioligands, there is a spectrum of PC disease in which PSMA expression is low or absent. The gastrin-releasing peptide receptor (GRPR), also known as the bombesin type 2 receptor, has been identified as a target in both the early and advanced stages of PC.

View Article and Find Full Text PDF

Development and Synthesis of Bombesin-Based Radiopharmaceutical Precursors Modified with Knottin.

Sovrem Tekhnologii Med

November 2024

DSc, Leading Researcher, Laboratory for Peptide Drugs and Vaccines Development, S.P. Kapitsa Research Institute of Technology; Ulyanovsk State University, 42 Leo Tolstoy St., Ulyanovsk, 432017, Russia.

Unlabelled: Bombesin receptors on the cell surface are of great interest as a target for targeted cancer therapy. One of the strategies of targeting bombesin receptors involves the use of tropic short peptides. However, the main limitation for the wide application of peptides as drugs is their low stability due to their sensitivity to extreme conditions of the internal body environment such as temperature and action of enzymes.

View Article and Find Full Text PDF

The gastrin-releasing peptide receptor (GRPR) is overexpressed in a variety of cancers and represents a promising target for diagnosis and therapy. However, the extremely high accumulation in the pancreas observed for most of the clinically evaluated GRPR-targeted radiopharmaceuticals could limit their applications. In this study, we synthesized one GRPR antagonist (ProBOMB5) and two GRPR agonists (LW02056 and LW02057) by replacing the 4-thiazolidinecarboxylic acid (Thz) residue in our previously reported GRPR-targeted tracers with Pro.

View Article and Find Full Text PDF
Article Synopsis
  • Prostate cancer (PCa) is a common cancer in men, and this study introduces iron oxide nanoparticles (IONs) designed to target the overexpressed Prostate Specific Membrane Antigen (PSMA) and Gastrin Releasing Peptide (GRP) receptors in PCa for better treatment options.
  • The researchers created different functionalized IONs that were tested for size, functionality, and radiolabeling efficiency, finding them to bind effectively to PCa cells while showing low toxicity.
  • The results indicate these Tc-radiolabeled IONs are stable and could be developed as diagnostic tools for PCa using Single Photon Emission Computed Tomography (SPECT) imaging.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!